COMPARISON
Ciclosporin vs Icatibant
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Ciclosporin is authorised or registered in 9 and Icatibant in 10 of the 10 registers read. Ciclosporin: highest phase Phase 4 (after approval). Icatibant: highest phase Phase 3 (3 phase 3 trials, 0 with posted results). 1 registered trial includes both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Ciclosporin | Icatibant | |
|---|---|---|
| Registered trials differs | 1328 clinicaltrials.gov · 2026-10-03 | 37 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA label, application not recorded: VEVYE openfda · 2026-08-31T07:37:14Z | FDA-approved: SAJAZIR openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2015-03-19 ema · 2026-10-03 | 2008-07-11 ema · 2026-10-03 |
| ATC code differs | S01XA18 ema · 2026-10-03 | B06AC02 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Ciclosporin | placebo | Icatibant | placebo |
|---|---|---|---|---|
| Punctate Keratitis | 5.8% | 4.5% | - | - |
| Hereditary angioedema | - | - | 18.1% | 18.7% |
| Headache | - | - | 10.1% | 6.7% |
Trial register Ciclosporin: 7 placebo-controlled trials; Icatibant: 4. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Ciclosporin side effects · Icatibant side effects
LEGAL STATUS
Approval in each country read
| Country | Ciclosporin | Icatibant | Register |
|---|---|---|---|
| United States | FDA label, application not recorded | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
1 registered trial includes both
| NCT04488081 | I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients ACTIVE_NOT_RECRUITING · updated 2026-03-16 |
|---|
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.